GE HealthCare Technologies Inc. (GEHC)

FairStock Score: 61/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach GE HealthCare as a medical-device franchise with products and services, but I want the numbers to prove durable economics. In fiscal 2025 (year ended 2025-12-31), revenue was $20.6B and net income $2.1B, or diluted EPS $4.55, up from $19.7B revenue and $2.0B net income in fiscal 2024. That is modest top-line progress, not rapid growth. The supplied FairStock Lynch category is Slow Grower — Shrinking, citing profit -1.9% a year over four years and revenue 4.1%, so I would not pay for a growth story. The balance sheet has debt/equity of 0.94 and FairStock Altman Z-Score 1.26, which calls for caution, though FairStock Piotroski F-Score 8/9 and trailing FCF of $1.6B, a 4.8% FCF yield, show cash generation. FairStock ROE is 19.38%, but ROCE is only 5.13%, suggesting returns on total capital are thin. At the close on 2026-10-26, price $71.98 gives P/E 16.59, P/B 2.96, EV/EBITDA 11.08 and FairStock Graham Number $48.71, a -46.68% margin of safety—not a bargain on that conservative math. In fiscal Q1 2026 (quarter ended 2026-03-31), revenue was $5.1B, net income $389.0M and diluted EPS $0.85; earlier quarters show uneven profits. I see a fair business, not a wide-moat bargain; patience and a lower price would be needed for a Graham-style margin of safety.

In plain English: GE HealthCare makes medical imaging and patient-care equipment and related digital services used in diagnosis and monitoring. The business earns solid profit on shareholders' money and produces cash, but profits have been uneven and it carries meaningful debt. At $71.98 on 2026-10-26, the price looks high compared with a simple value estimate, so it does not look clearly cheap.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · fiscal Q1 2025 10-Q (period ended 2025-03-31) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer